Prostate cancer is the second most common cancer among men in the United States and is most common in older men.1 Prostate-specific antigen (PSA) blood testing can be used as a screening tool to identify patients at high risk of developing prostate cancer.2 However, PSA-based screening is not standardly recommended for all men: the U.S. Preventive Services Task Force (USPSTF) recommends shared clinical decision-making between a physician and the patient to determine whether PSA screening should be performed.3
Our Epic Research Cancer Incidence Data Tracker tracks the rate of new prostate cancer diagnoses and PSA screenings each quarter over the past four years. The rates are stratified by age to better understand trends across different demographic groups.
Quarterly PSA screening rates increased across all age groups assessed between Q1 2021 and Q4 2025. Screening among men ages 55–64 increased the most over this period, increasing nearly 50% from 6,497.3 screenings per 100,000 encounters to 9,696.0 screenings per 100,000 encounters.
Over the same period, the rate of new prostate cancer diagnoses increased for men aged 55–64, 65–74, and 75–84, whose rate of new prostate cancer diagnoses increased 22%, 15%, and 12%, respectively.
You can stay up to date on the latest trends in cancer diagnoses and screenings with our Epic Research data tracker.
